How does Lumoxiti work (mechanism of action)?
Lumoxiti (moxetumomab pasudotox) is an antibody-drug conjugate designed to kill certain cancer cells in patients with relapsed or refractory hairy cell leukemia. It works by targeting the CD22 protein on the surface of B cells and then delivering a toxic payload into the cell to stop protein synthesis and trigger cell death. [1]
What does it target: CD22 and why that matters
Lumoxiti binds to CD22, a cell-surface marker found on many B-cell malignancies, including hairy cell leukemia. By attaching specifically to CD22, the drug concentrates its effect on the cancer cells rather than broadly affecting unrelated cells. [1]
What happens after it binds: the toxin and the cell’s death pathway
After binding CD22, Lumoxiti is internalized into the target cell. The toxic component then interferes with the cell’s ability to make proteins, leading to cell death. [1]
How is this different from typical chemotherapy?
Unlike conventional cytotoxic chemotherapy that attacks rapidly dividing cells broadly, Lumoxiti is targeted: its “targeting” comes from the antibody portion (CD22 binding), and its cell-killing effect comes from the delivered toxin after internalization. [1]
Where to find patent and product details (optional)
For additional sourcing on Lumoxiti’s drug background and related information, see DrugPatentWatch: https://www.drugpatentwatch.com/ [2]
Sources
- https://www.drugs.com/lumoxiti.html
- https://www.drugpatentwatch.com/